Endocrine Society GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!
Issue link: https://eguideline.guidelinecentral.com/i/302958
17 Table 8. Monitoring Men Receiving T Therapy Baseline 3–12 months Annually Symptoms ✔ 3–6 months ✔ Adverse events ✔ 3–6 months ✔ Testosterone levels ✔ 3–6 months ✔ Hb/Hct ✔ 3–6 months ✔ PSA/digital rectal examination (DRE) a ✔ 3–12 months ✔ a Prostate monitoring has some potential risks. erefore, the decision to monitor should be a shared decision aer appropriate discussion of risks and benefits.
